Clinical trials: Resectable Esophageal Cancer
Locally Advanced Unresectable Gastric Adenocarcinoma
Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer
The efficacy and safety of combination with Cadonilimab and CapeOX Regimen for neoadjuvant treatment of resectable locally advanced adenocarcinoma of the gastro-esophageal junction.
- Trial name
- NCT05974059
- Testing
- Oxaliplatin, Capecitabine, Cadonilimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Cancer, Esophageal Adenocarcinoma
TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
Despite treatment according to the CROSS-regimen, median overall survival is less than four years (2.3 QALYs). The burden of disease is within the highest category (0.71 to 1.0).
- Trial name
- TRAP-2 (NCT05188313)
- Testing
- Trastuzumab, Pertuzumab, Paclitaxel
- Where
- Netherlands
- Volunteers
- 376 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Esophageal Carcinoma
Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
To evaluate the efficacy and safety of neoadjuvant therapy of camrelizumab combined with chemotherapy for resectable locally advanced esophageal squamous cell carcinoma
- Trial name
- NCT05476380
- Testing
- camrelizumab
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Cancer, Malignant Neoplasm of Cardio-esophageal Junction of Stomach
Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer
The purpose of this study is to see whether giving azacitidine before each cycle of chemotherapy prior to surgery is safe.
- Trial name
- VEOX (NCT01386346)
- Testing
- Azacitidine, Oxaliplatin, Epirubicin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Weill Medical College of Cornell University
Stomach Cancer, Gastric Cancer
Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)
The goal of this clinical research study is to learn if a combination of 5-FU, Folinic Acid and Oxaliplatin, given with radiation therapy, is effective in the treatment of gastric or gastroesophageal cancers that will be removed…
- Trial name
- NCT00525785
- Testing
- 5-Fluorouracil, Folinic Acid, Oxaliplatin
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- M.D. Anderson Cancer Center
Adenocarcinoma of the Gastroesophageal Junction
Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction
The high cancer related mortality has remained a significant issue of health care in Poland, Europe and worldwide. The decreasing incidence rate for carcinoma of the distal stomach and a marked trend of increasing incidence for…
- Trial name
- NCT01523015
- Testing
- preoperative chemo- and chemoradiotherapy, Surgical resection
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Lublin
Resectable Esophageal Cancer
Study of Combination of Cetuximab and Radiotherapy Added to the Standard Treatment for Oesophageal Adenocarcinoma
The purpose of this study is to determine whether the addition of the combination between cetuximab and radiotherapy to the standard chemotherapy for resectable oesophageal cancer is safe and adds efficacy.
- Trial name
- TRACC (NCT00827671)
- Testing
- cetuximab, radiotherapy to oesophageal tumour
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- P.O. Witteveen
Gastric Cancer, Gastro-oesophageal Junction Cancer
Liquid Biopsy in Monitoring the Neoadjuvant Chemotherapy and Operation in Gastric Cancer
To explore the clinical value of dynamic detection of circulating tumor cells(CTCs), circulating tumor DNA(ctDNA) and cell-free DNA(cfDNA) in neoadjuvant chemotherapy and operation of resectable or locally advanced gastric or…
- Trial name
- NCT03957564
- Testing
- Neoadjuvant chemotherapy with PSOX regimen., Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in plasma., Detect the tumor related DNA in pathological tissues after operation.
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Affiliated Hospital of Qinghai University
Esophageal Squamous Cell Carcinoma
Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
To observe the 1-year disease-free survival rate （1-year PFS） of patients with resectable esophageal squamous cell carcinoma who received neoadjuvant chemoradiotherapy combined with camrelizumab and achieved clinical complete…
- Trial name
- WATCHER (NCT05507411)
- Testing
- Neoadjuvant Radiotherapy, Neoadjuvant Chemotherapy, Immunotherapy
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Zhejiang Cancer Hospital
Carcinoma of Esophagus
Pre-op Chemo-RT w/CDDP/5FU vs Chemo w/ Docetaxel/Irinotecan in PET Non Responder Resectable Esophagus Cancer
The purpose of this study is to improve their outcome by either changing the chemotherapy drugs or giving them radiation therapy with concurrent chemotherapy, hoping that this will improve their outcome.
- Trial name
- NCT01608464
- Testing
- irinotecan and docetaxel, Cisplatin, fluorouracil and concurrent radiation therapy
- Where
- Saudi Arabia
- Volunteers
- 170 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Esophageal Squamous Cell Carcinoma (ESCC)
Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma
This study is a randomized, controlled, open-label, multicenter Phase III clinical trial, designed to evaluate the efficacy and safety of neoadjuvant toripalimab in combination with nab-paclitaxel and platinum versus neoadjuvant…
- Trial name
- TD-NEOE3V3 (NCT06952621)
- Testing
- 3 cycles (Toripalimab + chemotherapy), 3 cycles（DCF）
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Tang-Du Hospital
Esophageal Squamour Cell Cancer
Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer
Neoadjuvant ChemoRadioTherapy (NCRT) combined with surgical resection is the standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC) based on CROSS and 5010 study.
- Trial name
- NCT06814158
- Testing
- Ivonescimab Combined With Chemotherapy
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Cancer
Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gefitinib before surgery may shrink the tumor so that it can be removed.
- Trial name
- NCT00258297
- Testing
- gefitinib, conventional surgery, enzyme inhibitor therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Rochester
Locally Advanced, Resectable
Ipromlimab and Tuvonralimab Combined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
This is a Phase II, single-arm clinical study designed to evaluate the efficacy and safety of Ipromlimab combined with Tuvonralimab, plus Albumin-Bound Paclitaxel and Nedaplatin, as neoadjuvant therapy for patients with locally…
- Trial name
- NCT07374003
- Testing
- lpromlimab and Tuvonralimab lpromlimab and Tuvonralimab Combined with Albumin-Bound Paclitaxel and Nedaplatin
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Sun Yat-sen University
Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
China with high incidence of esophageal cancer, the number of new cases and deaths account for about 50% of the world every year.
- Trial name
- NCT05659251
- Testing
- Serplulimab, Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy, Esophagectomy, sample
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
TDM of 5-FU, Pharmacokinetic Observational Study
Therapeutic Oncolytic Monitoring as a Tool for Effective Exposure to 5-FU in Patients With Locally Advanced, Resectable Gastric or Gastro-oesophageal Junction Cancer Treated With Perioperative FLOT
Traditional dosing of 5-FU is based on body surface area and DPD enzyme activity. However, BSA-based dosing is associated with wide inter-individual variations in 5-FU systemic exposure, and also 5-FU-induced toxicity.
- Trial name
- THOMAS FU FLOT (NCT05620524)
- Testing
- Extra blood samples for determining exposure to 5-FU
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
Esophageal Cancer
Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy
This study is a two arm, randomized, prospective, multicenter study on the perioperative treatment of locally advanced resectable esophageal cancer with penpulimab combined with anlotinib hydrochloride and chemotherapy.
- Trial name
- EASOPCWAAC (NCT06586242)
- Testing
- Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatin
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Xijing Hospital
Esophageal Squamous Cell Carcinoma
Prospective Trial to Evaluate the Safety and Efficacy to Treat Esophageal Cancer Using 5-FU, Oxaliplatin, and Docetaxel
The current multicenter prospective phase II study aims to evaluate the safety and efficacy of preoperative FLOT therapy for esophageal squamous cell carcinoma.
- Trial name
- NCT04699994
- Testing
- FLOT therapy
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- Keio University
First-line Treatment for Patients With Non-resectable Gastric Cancer or Cancer of the Esophagus or
Chemotherapy for Patients With Cancer of the Stomach
The purpose of this study is to determine maximal tolerable dose (MTD) of the combination of docetaxel, oxaliplatin and S1 (DOS) to patients with gastric cancer.
- Trial name
- DOS (NCT01928524)
- Testing
- DOS2w Dose level 1A, DOS2w Dose level 2A, DOS2w Dose level 3A
- Where
- Denmark
- Volunteers
- 34 people
- Sponsor
- Per Pfeiffer
Esophageal Squamous Cell Carcinoma (ESCC)
Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
This study aims to evaluate the efficacy and safety of neoadjuvant low-dose radiotherapy combined with Retlirafusp alfa and chemotherapy in the treatment of resectable locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT07682376
- Testing
- Low-dose radiotherapy + Retlirafusp alfa + nab-paclitaxel + cisplatin/carboplatin, Retlirafusp alfa + nab-paclitaxel + cisplatin/carboplatin
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Harbin Medical University